PhaseRx, Inc.
PZRXQ
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 12/31/2016 | 09/30/2016 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 4.70M | 5.25M | 12.58M | 11.67M | 10.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.04M | 13.64M | 20.13M | 18.33M | 16.74M |
| Operating Income | -13.04M | -13.64M | -20.13M | -18.33M | -16.74M |
| Income Before Tax | -13.89M | -14.48M | -22.03M | -20.14M | -18.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.89 | -14.48 | -22.03 | -20.14 | -18.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.89M | -14.48M | -22.03M | -20.14M | -18.92M |
| EBIT | -13.04M | -13.64M | -20.13M | -18.33M | -16.74M |
| EBITDA | -12.96M | -13.56M | -20.04M | -18.20M | -16.58M |
| EPS Basic | -1.19 | -1.24 | -2.78 | -6.62 | -10.55 |
| Normalized Basic EPS | -0.74 | -0.77 | -1.74 | -4.14 | -6.60 |
| EPS Diluted | -1.19 | -1.24 | -2.78 | -6.62 | -10.55 |
| Normalized Diluted EPS | -0.74 | -0.77 | -1.74 | -4.14 | -6.60 |
| Average Basic Shares Outstanding | 46.76M | 46.76M | 41.08M | 29.93M | 18.77M |
| Average Diluted Shares Outstanding | 46.76M | 46.76M | 41.08M | 29.93M | 18.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |